Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9OJS

Crystal structure of TNF alpha in complex with compound 4

This is a non-PDB format compatible entry.
Summary for 9OJS
Entry DOI10.2210/pdb9ojs/pdb
Related9OJO
DescriptorTumor necrosis factor, (6R,13R,14R)-10-fluoro-11-[2-(2-hydroxypropan-2-yl)pyrimidin-5-yl]-7H-6,14-methanopyrido[3',2':4,5]imidazo[1,2-b][2,5]benzodiazocin-5(14H)-one (3 entities in total)
Functional Keywordstumor necrosis factor alpha, structure-based drug design, cytokine
Biological sourceHomo sapiens (human)
Total number of polymer chains3
Total formula weight52936.00
Authors
Judge, R.A.,Longenecker, K.L. (deposition date: 2025-05-08, release date: 2025-07-23)
Primary citationBian, Z.,Schmidt, R.G.,Wilson, N.S.,Duignan, D.B.,Breinlinger, E.,Dombrowski, A.W.,Erdman, P.,Foley, C.M.,Friedman, M.,Gfesser, G.A.,Goess, C.A.,Gomtsyan, A.,Judge, R.A.,Kikuchi, R.,Koshman, Y.,Liu, X.,Longenecker, K.L.,McClure, A.,Sippy, K.,Wetter, J.M.,Stoffel, R.,Vasudevan, A.
Discovery of Orally Efficacious Bridged Piperazines as smTNF Modulators.
J.Med.Chem., 2025
Cited by
PubMed Abstract: Tumor necrosis factor α (TNFα) plays a critical role in inflammatory and autoimmune diseases. While biologic drugs have improved patient outcomes in conditions like rheumatoid arthritis by disrupting TNFα signaling, small molecule targeting has been challenging due to the strong TNF-receptor binding and difficulty in disrupting the TNF trimer. This research presents small molecule TNFα inhibitors with a novel bridged-piperazine core, developed through molecular dynamics simulation and scaffold hopping. The initial hit was optimized using structure-based design, leading to the discovery of a lead molecule with similar potency to the prototype but enhanced physicochemical properties. This lead demonstrated oral efficacy in a mouse glucose-6-phosphate isomerase-induced paw swelling model, comparable to the effects of a TNFα antibody. The estimated effective human dose is 200 mg once daily, highlighting the potential for clinical development of these compounds.
PubMed: 40632677
DOI: 10.1021/acs.jmedchem.5c00323
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.849 Å)
Structure validation

239149

数据于2025-07-23公开中

PDB statisticsPDBj update infoContact PDBjnumon